QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (44) Citing Articles via Google Scholar Google Scholar Articles by Gilbert, M. R. Articles by Zaknoen, S. L. Search for Related Content PubMed PubMed Citation

A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy

The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030 (M.R.G., J.F.K.); Brain Tumor Center at Duke University, Durham, NC 27710 (H.S.F.); University of California at San Francisco, San Francisco, CA 94143 (M.D.P.); Emory University, Atlanta, GA 30322 (J.J.O.); Children's National Medical Center, The George Washington University, Washington, DC 20010 (G.H.R.); Schering-Plough Research Institute, NJ 07033-1300 (S.L.Z.)

¹ Address correspondence and reprint requests to Mark R. Gilbert, Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030-4009.

Abstract

Temozolomide is a novel second-generation oral alkylating agent with demonstrated efficacy and safety in patients with recurrent glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA). A multicenter phase II trial was conducted to determine the efficacy and safety of temozolomide before radiotherapy in patients with newly diagnosed GBM and AA. Fifty-seven patients (51 adult, 6 pediatric) with newly diagnosed supratentorial GBM or AA were treated with temozolomide (200 mg/m² per day for 5 consecutive days every 28 days) for a maximum of 4 cycles. All patients were then treated with external beam radiotherapy. Twenty-two patients (39%) achieved objective response, including 6 (11%) with complete response (CR) and 16 (28%) with partial response (PR). Additionally, 18 (32%) patients had stable disease (SD). Of 21 patients (18 adult, 3 pediatric) with AA, 2 (10%) achieved CR, 5 (24%) achieved PR, and 8 (38%) had SD. Among adult patients with AA, the median progression-free and overall survival rates were 7.6 and 23.5 months, respectively. Among 36 patients (33 adult, 3 pediatric) with GBM, 4 (11%) had CR, 11 (31%) had PR, and 10 (28%) had SD. The median progression-free and overall survival rates among adult patients with GBM were 3.9 and 13.2 months, respectively. Temozolomide was safe and well tolerated in adult and pediatric patients. Grades 3 and 4 adverse events were reported in 16 (28%) and 7 (12%) patients, respectively. Temozolomide was safe and effective in treating newly diagnosed GBM and AA before radiotherapy. This pre-irradiation treatment approach appears promising, but will require additional evaluation in comparative studies.

This article has been cited by other articles:

				O. L. Chinot, M. Barrie, S. Fuentes, N. Eudes, S. Lancelot, P. Metellus, X. Muracciole, D. Braguer, L. Ouafik, P.-M. Martin, et al. Correlation Between O6-Methylguanine-DNA Methyltransferase and Survival in Inoperable Newly Diagnosed Glioblastoma Patients Treated With Neoadjuvant Temozolomide J. Clin. Oncol., April 20, 2007; 25(12): 1470 - 1475. [Abstract] [Full Text] [PDF]

				M. Barrie, C. Couprie, H. Dufour, D. Figarella-Branger, X. Muracciole, K. Hoang-Xuan, D. Braguer, P. M. Martin, J. C. Peragut, F. Grisoli, et al. Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme Ann. Onc., July 1, 2005; 16(7): 1177 - 1184. [Abstract] [Full Text] [PDF]

				M. Brada, S. Ashley, A. Dowe, A. Gonsalves, A. Huchet, G. Pesce, M. Reni, F. Saran, B. Wharram, M. Wilkins, et al. Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide Ann. Onc., June 1, 2005; 16(6): 942 - 949. [Abstract] [Full Text] [PDF]

				M. S. Bobola, J. R. Silber, R. G. Ellenbogen, J. R. Geyer, A. Blank, and R. D. Goff O6-Methylguanine-DNA Methyltransferase, O6-Benzylguanine, and Resistance to Clinical Alkylators in Pediatric Primary Brain Tumor Cell Lines Clin. Cancer Res., April 1, 2005; 11(7): 2747 - 2755. [Abstract] [Full Text] [PDF]

				P. A. Robe, M. Bentires-Alj, M. Bonif, B. Rogister, M. Deprez, H. Haddada, M.-T. N. Khac, O. Jolois, K. Erkmen, M.-P. Merville, et al. In vitro and In vivo Activity of the Nuclear Factor-{kappa}B Inhibitor Sulfasalazine in Human Glioblastomas Clin. Cancer Res., August 15, 2004; 10(16): 5595 - 5603. [Abstract] [Full Text] [PDF]

				J. J. Raizer, M. G. Malkin, M. Kleber, and L. E. Abrey Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy Neuro-oncol, July 1, 2004; 6(3): 247 - 252. [Abstract] [PDF]

				A. Broniscer and A. Gajjar Supratentorial High-Grade Astrocytoma and Diffuse Brainstem Glioma: Two Challenges for the Pediatric Oncologist Oncologist, April 1, 2004; 9(2): 197 - 206. [Abstract] [Full Text] [PDF]